448 related articles for article (PubMed ID: 20306249)
21. Thermodynamic investigation of DNA-binding affinity of wild-type and mutant transcription factor RUNX1.
Wu F; Song T; Yao Y; Song Y
PLoS One; 2019; 14(5):e0216203. PubMed ID: 31048839
[TBL] [Abstract][Full Text] [Related]
22. Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.
Hyde RK; Zhao L; Alemu L; Liu PP
Leukemia; 2015 Aug; 29(8):1771-8. PubMed ID: 25742748
[TBL] [Abstract][Full Text] [Related]
23. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
[TBL] [Abstract][Full Text] [Related]
24. The role of CBFbeta in AML1-ETO's activity.
Park S; Speck NA; Bushweller JH
Blood; 2009 Sep; 114(13):2849-50. PubMed ID: 19779050
[No Abstract] [Full Text] [Related]
25. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes.
Kwok C; Zeisig BB; Qiu J; Dong S; So CW
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2853-8. PubMed ID: 19202074
[TBL] [Abstract][Full Text] [Related]
26. Emerging therapies for inv(16) AML.
Surapally S; Tenen DG; Pulikkan JA
Blood; 2021 May; 137(19):2579-2584. PubMed ID: 33821975
[TBL] [Abstract][Full Text] [Related]
27. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
28. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
29. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.
Cunningham L; Finckbeiner S; Hyde RK; Southall N; Marugan J; Yedavalli VR; Dehdashti SJ; Reinhold WC; Alemu L; Zhao L; Yeh JR; Sood R; Pommier Y; Austin CP; Jeang KT; Zheng W; Liu P
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14592-7. PubMed ID: 22912405
[TBL] [Abstract][Full Text] [Related]
30. A novel RUNX1-C11orf41 fusion gene in a case of acute myeloid leukemia with a t(11;21)(p14;q22).
Abe A; Katsumi A; Kobayashi M; Okamoto A; Tokuda M; Kanie T; Yamamoto Y; Naoe T; Emi N
Cancer Genet; 2012 Nov; 205(11):608-11. PubMed ID: 23102734
[TBL] [Abstract][Full Text] [Related]
31. RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes.
Jenkins CE; Gusscott S; Wong RJ; Shevchuk OO; Rana G; Giambra V; Tyshchenko K; Islam R; Hirst M; Weng AP
Exp Hematol; 2018 Aug; 64():84-96. PubMed ID: 29733873
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of core binding factorβ alters sphingolipid metabolism.
Greer AH; Yong T; Fennell K; Moustafa YW; Fowler M; Galiano F; Ng SW; Berkowitz RS; Cardelli J; Meyers S; Davis JN
J Cell Physiol; 2013 Dec; 228(12):2350-64. PubMed ID: 23813439
[TBL] [Abstract][Full Text] [Related]
33. The core binding factor CBF negatively regulates skeletal muscle terminal differentiation.
Philipot O; Joliot V; Ait-Mohamed O; Pellentz C; Robin P; Fritsch L; Ait-Si-Ali S
PLoS One; 2010 Feb; 5(2):e9425. PubMed ID: 20195544
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
35. A distinct epigenetic signature at targets of a leukemia protein.
Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N
BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773
[TBL] [Abstract][Full Text] [Related]
36. New mechanisms of AML1 gene alteration in hematological malignancies.
Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
[TBL] [Abstract][Full Text] [Related]
37. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
[TBL] [Abstract][Full Text] [Related]
38. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
39. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
40. RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.
Koh CP; Wang CQ; Ng CE; Ito Y; Araki M; Tergaonkar V; Huang G; Osato M
Leukemia; 2013 Sep; 27(9):1793-802. PubMed ID: 23817177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
